Dainippon and Eisai Signed Licensing Agreement
|Dainippon Pharmaceutical Co., Ltd.
Public Relations Dept.
Doshomachi 2-6-8, Chuo-ku, Osaka
|Eisai Co., Ltd.|
Corporate Communications Dept.
Koishikawa 4-6-10, Bunkyo-ku, Tokyo
[Notes to editors]
- What is diabetic neuropathy?
One of three major diabetic complications along with retinopathy and nephropathy. Patients with diabetes can develop diabetic neuropathy at high rates (approximately 40%), accompanied by symptoms such as numbness and pain in the hands, arms, feet and legs and postural hypotension, which can result in a worsening of patients' quality of life. If left untreated, diabetic neuropathy can lead to gangrene in the foot or leg, which may require amputation in severe cases.
There are no effective treatments for advanced diabetic neuropathy, thus it is important for patients to be diagnosed and treated in the early stages.